BrainParrot

Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;

GS2Full notePublished: · Updated:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • NPPA capped trade margins on the MRP of 137 non-scheduled anti-cancer drugs. The revised prices take effect on 9 November 2026.
  • So far, 76 companies have reported revised MRPs for 1,225 formulations, and 1,031 of these show a reduction. Consumers are estimated to save about ₹3,502 crore a year.
  • Retailers, hospitals and institutions must display the revised MRP lists, and State Drug Controllers will monitor compliance.

UPSC relevance: GS2 — Social Justice/Health: affordability and access to medicines; GS3 — Economy: price regulation

Key facts for Prelims

  • NPPA is under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
  • DPCO 2013: Paragraph 19 is the source of the extraordinary power. Paragraph 20(1) governs annual price increases, which the release says manufacturers can still take, provided the maximum trade margin of 30% is observed.
  • TMR applies to non-scheduled drugs. The notification is SO 5690(E) dated 17 October 2026, and it stays in force until further orders.
  • Expert Committee formed by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare, recommended the drug list.
  • Consumer tools: Pharma Sahi Daam mobile app and www.nppa.gov.in. The release gives a postal address for complaints (Deputy Director, Monitoring, NPPA, New Delhi).
  • State Drug Controllers monitor compliance by manufacturers, dealers, hospitals and medical institutions.
  • Examples named: Bevacizumab 100 mg injection (lung, colon, ovary and cervical cancer); Denosumab 60 mg injection (breast and prostate cancer; prevents bone loss); Pegfilgrastim 6 mg injection (prevents neutropenia in cancer patients).

Data and details

  • Coverage: 137 drugs identified. 10–15 are yet to be launched in India, but TMR will apply to them whenever they launch.
  • Company reports so far: 76 companies reported revised MRPs for 1,225 formulations covering 121 drugs. Reduction reported in 1,031 formulations; 600 brands show reductions above 50%; the highest reduction is 96.45%. By simple subtraction, the other 194 formulations did not report a reduction.
  • Savings: estimated ₹3,502.31 crore per year for consumers.
  • Margin cap: 30% maximum permissible trade margin.
  • Effective date: 9 November 2026.
  • Display and compliance: every retailer, dealer, hospital and institution must display the revised MRP list on websites and premises.

Static–dynamic linkage

  • Drug price regulation in India works at two levels. Ceiling prices are fixed for essential medicines (scheduled formulations). For non-scheduled drugs, the state mostly monitors price increases and has used a targeted tool, Trade Margin Rationalisation (TMR), to cap the markup between the price to retailer and MRP.
  • TMR does not set the manufacturer's price. It curbs distribution-chain markups, which are a major cause of out-of-pocket health spending.

Syllabus mapping: GS2 – Governance/Social Justice: Health, welfare and role of regulators | GS3 – Economy: Price controls and market regulation; Essential Commodities Act | Polity: statutory/executive bodies and delegated legislation (Drug Price Control Order)

Background primer

National Pharmaceutical Pricing Authority (NPPA)

What it is:
An attached office of the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers) that enforces the Drugs (Prices Control) Order, 2013.
Founded:
1997, through a Government of India Resolution dated 29 August 1997, as an expert body for price control of essential and life-saving medicines.
Mandate:
Fix ceiling prices of medicines in the National List of Essential Medicines (NLEM) incorporated in Schedule-I of the DPCO, 2013. It also monitors non-scheduled formulations so that MRP does not rise more than 10% in a twelve-month period.
Why it matters:
Keep essential medicines affordable while allowing a workable pharma market.

Drugs (Prices Control) Order, 2013 (DPCO)

What it is:
An order issued under the Essential Commodities Act, 1955. Paragraph 19 lets the Central Government fix or revise a drug's price in extraordinary circumstances in the public interest.

Additional context

  • The 2019 pilot. In February 2019 NPPA invoked Paragraph 19 to bring 42 non-scheduled anti-cancer drugs under a trade margin cap of up to 30% of MRP. It was explicitly a pilot for "proof of concept". The 42-drug cap reduced MRP by up to 90% for 526 brands. A later PIB reply estimated annual savings of about ₹984 crore.
  • Current notification. NPPA capped the margin at 30% of MRP under Paragraph 19 of DPCO 2013. PIB's October 2026 release named widely used drugs such as Pembrolizumab, Durvalumab and Osimertinib.
  • Why the intervention was thought necessary. An NPPA analysis, cited when the 30% cap was approved in principle on 8 October 2026, found average markups of about 170% on non-scheduled cancer drugs, with some reaching 700%.
  • Supply safeguard. NPPA's 17 October 2026 release directed manufacturers to maintain current production and supply levels of the notified formulations, so that the cap does not cause artificial shortages.
  • Parliamentary view on permanence. In its report of 6 August 2026, the Standing Committee on Chemicals and Fertilizers noted that TMR has been used only as a pilot and that there is no set timeframe for building a permanent TMR framework into DPCO 2013. It also noted that hospitals and retailers offer discounts of 20–60% on MRP, which indicates large built-in margins.

Mains dimensions

  • Health affordability: out-of-pocket spending is a major driver of catastrophic health expenditure. Capping the trade margin addresses the gap between price to retailer and MRP.
  • Scale-up from pilot to broad coverage: 42 drugs in 2019 to 137 in 2026. The 600 brands with reductions above 50% and the 96.45% maximum show how large some margins were.
  • Regulatory design: TMR acts on the distribution chain, not on the manufacturer's price. It cannot fix high factory prices. It sits between full ceiling pricing for NLEM drugs and light-touch monitoring for the rest. The 10–15 unlaunched drugs are covered in advance.
  • Implementation challenges:
  • Compliance depends on State Drug Controllers.
  • Retail display of revised prices and consumer awareness (Pharma Sahi Daam app).
  • Manufacturers may take annual increases under Paragraph 20(1) while observing the 30% margin.
  • Supply-side risks such as shortages or brand substitution are not discussed in this release. NPPA's earlier 17 October release asked manufacturers to maintain production and supply levels, so continued availability needs monitoring.
  • Legal basis: reliance on an extraordinary power (Paragraph 19) repeatedly, rather than a standing framework, raises questions of certainty and legal durability. The Standing Committee flagged the lack of a timeline for a permanent TMR framework.
  • Way forward: write TMR into DPCO 2013 as a permanent mechanism, broaden data coverage, pair with generic and Jan Aushadhi promotion, and monitor availability alongside prices.

Possible Mains question

**GS2, 15 marks:** "Trade Margin Rationalisation has been extended to 137 anti-cancer drugs. Examine the rationale, the legal basis and the limitations of this approach in making essential medicines affordable in India."

Related topics

  • National List of Essential Medicines (NLEM) and scheduled vs non-scheduled formulations
  • National Pharmaceutical Pricing Policy, 2012
  • Essential Commodities Act, 1955
  • Out-of-pocket expenditure and Ayushman Bharat PM-JAY
  • Jan Aushadhi scheme and generic medicines
  • National Programme for Prevention and Control of Non-Communicable Diseases (cancer)

Practice questions

  1. 1. With reference to the trade margin rationalization of anti-cancer drugs in India, consider the following statements: 1. The revised prices of these drugs came into effect from 9th December, 2026. 2. The NPPA capped trade margins on the maximum retail price (MRP) of 137 anti-cancer drugs. 3. As a result of the price reductions, the estimated annual savings to consumers would be ₹3,502.31 crore. Which of the statements given above is/are correct?
    Show answer

    Answer: (A) 2 and 3 only

    Explanation: Statement 1 is incorrect — the source states: The revised prices of these drugs will come into effect from 9th November, 2026.. Statement 2 is correct: National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026.. Statement 3 is correct: As a result of the price reductions to be effected from 9th November, 2026, the estimated annual savings to consumers would be ₹3,502.31 crore..

  2. 2. Consider the following statements: 1. Every retailer, dealer, hospital and institution is required to display the Revised MRP list of anti-cancer medicines on their websites and in their premises. 2. Consumers can check the applicable prices of these medicines only through the NPPA website. 3. The trade margins on the MRP of 137 anti-cancer drugs were capped based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health & Family Welfare. Which of the statements given above is/are correct?
    Show answer

    Answer: (D) 1 and 3 only

    Explanation: Statement 1 is correct: Every retailer, dealer, hospital and institution is required to prominently display Revised MRP list of anti-cancer medicines on their websites and in their premises.. Statement 2 is incorrect — the source states: Consumers can check the applicable prices through the Pharma Sahi Daam mobile application and the NPPA website ( www.nppa.gov.in ) and report any non-compliance or violation of revised prices to the authority.. Statement 3 is correct: National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026..

  3. 3. Consider the following pairs: List I (Anti-cancer drug) — List II (Therapeutic use) 1. Bevacizumab — A. Prevention of neutropenia in cancer patients 2. Denosumab — B. Lung, colon, ovary and cervical cancer 3. Pegfilgrastim — C. Breast and prostate cancer and prevention of bone loss Which of the pairs given above is/are correctly matched? Select the answer using the code given below.
    Show answer

    Answer: (B) 1-B, 2-C, 3-A

    Explanation: The only fully correct pairing is 1-B, 2-C, 3-A. Bevacizumab 100 MG Injection is used for lung, colon, ovary and cervical cancer; Denosumab 60 MG Injection is used for breast and prostate cancer and prevents bone loss; Pegfilgrastim 6 MG Injection is used to prevent neutropenia in cancer patients. Every other code attaches at least one drug to another drug's indication (e.g., 1-A wrongly gives neutropenia prevention to Bevacizumab, which is Pegfilgrastim's indication).

Topics: GS2

How we write and check these notes →

All current affairs of 7 November 2026 → · UPSC Current Affairs